GPX4 ‐Mediated Inhibition of Ferroptosis by Sodium Selenite Ameliorates Bone Metabolic Disorders in Ovariectomized Mice
Journal of Cellular and Molecular Medicine · 2026-10 · 30 (20)
DOI: 10.1111/jcmm.71414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 19.10.2026. Verfasst von Wei Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Orthopedic Surgery, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Phospholipid Hydroperoxide Glutathione Peroxidase, Ferroptosis, Sodium Selenite, Bone Diseases, Metabolic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2025 Suzhou Medical and Industrial Cooperation Innovation Project.
Abstract (Originalsprache)
Postmenopausal osteoporosis (PMOP) and its associated fracture complications have emerged as pressing public health challenges due to rapidly accelerating global population ageing. The functional decline of bone marrow mesenchymal stem cells (BMSCs) under elevated oxidative stress is a recognised pathogenic cornerstone of PMOP, positioning redox imbalance as a critical therapeutic node. Here, we establish that sodium selenite (Na 2 SeO 3 ) robustly counters oxidative insults in BMSCs, thereby restoring and enhancing their osteogenic lineage commitment. Furthermore, RNA sequencing analysis indicated that ferroptosis may be mechanistically associated with the underlying cellular responses. Ferroptosis is critically mediated by glutathione peroxidase 4 (GPX4), a selenoenzyme that functions as its principal enzymatic suppressor. Silencing GPX4 in BMSCs markedly reduced their osteogenic capacity and simultaneously upregulated ferroptotic protein expression. Notably, this impairment was not reversed by Na 2 SeO 3 administration under conditions of GPX4 suppression. These findings suggest that Na 2 SeO 3 enhances osteogenic differentiation primarily by upregulating GPX4 expression, thereby inhibiting ferroptosis. Thus, we have established Na 2 SeO 3 as a potential therapeutic strategy for PMOP by identifying a previously unrecognised molecular axis through which selenium regulates bone metabolic homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Orthopedic Surgery, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
- The Department of Orthopedic Surgery, Taizhou Fourth People's Hospital, Taizhou, Jiangsu, China.
- The Department of Orthopaedic Surgery, Orthopaedic Institute, the First Affiliated Hospital, Suzhou Medical College, Soochow University, Suzhou, Jiangsu, China.
- College of Chemistry, Chemical Engineering and Materials Science Soochow University, Suzhou, People's Republic of China.
ORCID-Profile: Wei Luo, Xin Liu, Xiangqiang Pan, Dechun Geng, Hanliang He
Förderung
- 2025 Suzhou Medical and Industrial Cooperation Innovation Project
Zitieren
APA
Luo, W., Xu, H., Liu, X., Zhang, Y., Zhou, H., Pan, X., Geng, D., & He, H. (2026). GPX4 ‐Mediated Inhibition of Ferroptosis by Sodium Selenite Ameliorates Bone Metabolic Disorders in Ovariectomized Mice. Journal of Cellular and Molecular Medicine, 30(20). https://doi.org/10.1111/jcmm.71414
Vancouver
Luo W, Xu H, Liu X, Zhang Y, Zhou H, Pan X, et al. GPX4 ‐Mediated Inhibition of Ferroptosis by Sodium Selenite Ameliorates Bone Metabolic Disorders in Ovariectomized Mice. Journal of Cellular and Molecular Medicine. 2026;30(20). doi:10.1111/jcmm.71414
BibTeX
@article{Luo2026,
author = {Luo, Wei and Xu, Haibo and Liu, Xin and Zhang, Yongsheng and Zhou, Hao and Pan, Xiangqiang and Geng, Dechun and He, Hanliang},
title = {GPX4 ‐Mediated Inhibition of Ferroptosis by Sodium Selenite Ameliorates Bone Metabolic Disorders in Ovariectomized Mice},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {20},
doi = {10.1111/jcmm.71414}
}
EUVIMED